Open Clinical Trials

Blinded Reference Set For Multicancer Early Detection Blood Tests

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or more Brain Metastases

Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity ≥4 Brain Metastases/Year

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

All-in-One nanoparticles for breast cancer treatment based on phototherapy and chemodynamic therapy

Breast Cancer Bone Metastasis Testbeds

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer and T3N0 Breast Cancer

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer

Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices On Incorporating Chemoprevention into Care (MiCHOICE)

(CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)

A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast Cancer (KEYNOTE-B49)

Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation

SH ABCD: Autoantibodies in Breast Cancer Detection

Evaluating the Safety and Efficacy of a Novel IMRT/VMAT-based APBI Regimen for Patients with Favorable Risk Early Stage Breast Cancer

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

Investigating the role of platelets in cancer patients undergoing treatment with PD-1/PD-L1 inhibitors

Chemotherapy Delivery via Engineered Nano-missiles for Halting Progression of Pancreatic Cancer

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Ostomy Telehealth Self-Management Training for Cancer Survivors

SH Nucleotides in Colorectal Cancer

Prospective cohort study embedded into integrated health care systems in the US to study cancer etiology, prevention, and early detection (Study Documentation avail-see Clinical Research)

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors

A Phase 3, Randomized Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or TAS-102 as Third-line Treatment for Participants with Previously Treated Metastatic Colorectal Cancer

AKT/mTOR Pathway in Obesity and Colorectal CancEr (CRC): Molecular IntercONnections and Potential Clinical Applications

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients

A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)

A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

An Exploration of Rural-Urban Disparities in Colorectal Cancer Care in North Dakota through participant surveys

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Bone Metastasis Testbed for Regenerative Bone Therapies for Bone Metastasis

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

A Prospective Observational Cohort Study to Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

A Multi-Center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK-3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022)

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)

A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Sanford Genomic Consortium Collaborative Project-Immune Profiling in Primary Immunodeficiency

COMPASS: Community Oncology use of Molecular Profiling to Personalize the Approach to Specialized cancer treatment at Sanford

The OVAL study: A Randomized, Controlled, Double-arm, Double-blind, Multi-Center study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

A Phase 3, Randomized, Open-Label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

A Randomized, Phase 2 Study of Pembrolizumab and Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High Grade Serous Ovarian Cancer

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Role of tumor microenvironment on tumor progression, drug resistance and immune escape

CTR H&N Cancer Prehab

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC

Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

A Phase 3, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer

Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT In Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH HIGH-DOSE CISPLATIN (100 MG/M2) EVERY THREE WEEKS VERSUS RADIATION WITH LOW-DOSE WEEKLY CISPLATIN (40 MG/M2) FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

SH Dr. Spanos Chemokine

Evaluation of the long-term tumor control of de-escalated head and neck irradiation in p16 positive oropharynx cancer in patients with minimal/no-nicotine use history

SH Understanding and Improving Cancer Treatment of Solid Tumor Cancers

Implementation and Effectiveness Trial of HN-STAR

ATHN 10: Leveraging the ATHNdataset to Document the State of Rare Coagulation Disorders in the United States

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma

The National Myelodysplastic Syndromes (MDS) Study

A Phase 2 Study to Evaluate the Safety and Efficacy of MK-1026 in Participants with Hematologic Malignancies

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 in Participants with Selected Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

CTR DELIVER: Tumor-Directed Delivery Method for Effective Management of Lung Cancer Sponsor: Sanford Health

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Study of Pembrolizumab with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib in Stage III NSCLC

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Humanitarian Use Device: Optune Lua

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

A Randomized, Open-Label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PAPILLON)

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation

CTR FAIR CAP: Defining the role of Intergrin-talin1 complex in renal cancer progression and fibrosis

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)

To investigate the efficacy of RAGE inhibitors combined with standard of care melanoma drugs in human patient derived xenograft models of melanoma

STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or Cetuximab in Participants with Advanced Solid Tumors

A Phase 1 Study of BMS-986406, an ILT4 Myeloid-specific Antibody, as Monotherapy and Combination Therapies in Participants with Advanced Solid Tumors

A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors

A Multicenter, Open-label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors

A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With An Anti-PD-1 Therapy

Tempus TIME A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

CIBMTR Research Database

Umbrella Long-Term Follow-Up Protocol

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

COG ACCL2031 A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients

A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) associated Low-Grade Glioma (LGG)

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

A Phase 3 Study of Selumetinib (NSC# 74827, IND#77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressiv Low-Grad Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

COG ACNS2021, A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features

StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors

Tool for monitoring Chemotherapy Induced Peripheral Neuropathy (CIPN)

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Key Adverse Events after Childhood Cancer

Rapid Whole Genome Sequencing (rWGS): Rapid Genomic Sequencing for Acutely Ill Patients and the Collection, Storage, Analysis, and Distribution of Biological Samples, Genomic and Clinical Data

EVALUATION OF LONG-TERM SAFETY IN PAEDIATRIC SUBJECTS WITH B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA(ALL) WHO HAVE BEEN TREATED WITH EITHER BLINATUMOMAB BLINCYTO OR CHEMOTHERAPY, FOLLOWED BY TRANSPLANTATION (OBSERVATIONAL STUDY)

International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP)

Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphonma.

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Comparison of antibodies against SARS-CoV-2 in cancer and non-cancer pediatric patients in South Dakota

SH Dr. Lopez Pediatric Immune Response during Lower Respiratory Tract Infection (LRTI)

OBSERVATIONAL STUDY OF PEDIATRIC RHEUMATIC DISEASES THE CARRA REGISTRY

Renal Tumors Classification, Biology, and Banking Study

Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Neuroblastoma Biology Studies

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

ARDS in Children and ECMO initiation strategies impact on Neuro-Development (ASCEND)

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

AGCT1532, Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamine (VINO-AC) plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-Cpo) vs Vincristine, Dactinomycin and Cyclophosphamine (VAC) plus VINO-Cpo Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Cincinnati Children’s Sickle Cell Disease Caregiver Immunization Survey

SH Dr. Griffin PLEDGE Monitoring

Sanford Population Level Estimate of Type 1 Diabetes Risk GEnes in Children

Natural History Study of The Development of Type 1 Diabetes

Limited access protocol for the use of oral cisapride in the treatment of pediatric patients with refractory gastroesophageal reflux disease and other gastrointestinal motility disorders.

Effect of Vagus Nerve Preservation During Gastric Bypass on Gastrin Level and Marginal Ulcer Formation

Impact of a PGx Clinic visit on PGx Guided Medication Outcomes

SH Sanford Polygenic Risk ScOre ReTurn of REsults for Coronary Artery Disease

Evaluate expanding the indication of the CardioMEMS™ Heart Failure System to NYHA Class II, III, and IV patients with either a prior HF hospitalization or an elevated BNP.

Validation of CardioMEMS HF System Cardiac Output Algorithm (VICTOR) IDE

A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF ≥40%)

PK Papyrus Covered Coronary Stent System is a Humanitarian Use Device approved under a Humanitarian Device Exemption

Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP II TR): A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation

Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-Vitamin K Antagonist Oral Anticoagulants

AnaLysIs of Both Sex and Device Specific FactoRs on Outcomes in PAtients with Non-Ischemic Cardiomyopathy

I-SPY COVID19 Response in an Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

NIH RECOVER: A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults

Multiple Patient Program for Lamprene (clofazimine) forthe treatment of Non-Tuberculous

A Safer Effective Method to Control the Serum Bilirubin of Extremely Premature Infants?

Milrinone in Congenital Diaphragmatic Hernia

SONPM National Registry for Perinatal COVID -19 Infections

All Birth Cohort (ABC) Study

Randomized Placebo-controlled Trial to Shorten Pharmacologic Treatment of Newborns with Neonatal Opioid Withdrawal Syndrome (NOWS)

FOLLOW-UP STUDY Follow-up Visit of High Risk Infants

Survey of Morbidity and Mortality among high risk preterm infants

Study of Attitudes and Factors Effecting Preterm Infant Care Practices

Randomized Study of IN.PACT AV Access Paclitaxel coated percutaneous Transluminal Angioplasty Balloon vs Standard PTA for the Treatment of Obstructive Lesions in the Native Arteriovenous Dialysis Fistulae Drug Coated Balloon to treat obstruction of de novo or non-stented restenotic arteriovenous fistulae

A Phase 3B, Multicenter, Open-Label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants with Relapsing Forms of Multiple Sclerosis who Receive Oral Ozanimod Compared to Non-Pegylated Interferon-β or No Disease Modifying Therapy

A Prospective Registry Study in a Global Huntingtons Disease Cohort A CHDI Foundation Project

Development of the Virtual Unified Huntington Disease Rating Scale (vUHDRS™)

HUMANITARIAN USE DEVICE: PulseRider Aneurysm Neck Reconstruction Device

Defining clinically significant fatigue in Parkinson’s disease

SH UND Pathophysiology of orthostatic hypotension in Parkinson’s Disease

Post-approval Registry Study to Evaluate the Continued Safety and Probable Benefit of the MID-C System for 5 Years Post-Implantation in Adolescent Idiopathic Scoliosis (AIS)

Minimally Invasive Deformity Correction (MID-C) System – H170001

MILES Extension Study: Two and Three Year Follow Up in subjects who previously received Mesenchymal Stem Cells or Corticosteroid Injection as part of the MILES randomized clinical trial

RC-004: A Longitudinal, Multi-Center Safety Study of Autologous Adult Adipose-Derived Regenerative Cell Injection into Chronic Partial-Thickness Rotator Cuff Tears

The Effects of Combination Therapy of Opioids versus Non-Opioids on Postoperative Pain Management after Knee Arthroscopic Surgery: A Prospective Randomized Controlled Study

Vertebral Body Tethering System

SH Dr. Thayne Munce USD Neuroimaging for MMA Fighters

SH Direct Resuscitation of the Open Peritoneum The DROP Trial

A Prospective Study of Emergency Department / Urgent Care Revisit Rates among Discharged Rib Fracture Patients with Involvement of Community Paramedics

Radiographic Evaluation of Delayed Solid Organ Complications (REDSOC) Study

Randomized Study of IN.PACT AV Access Paclitaxel coated percutaneous Transluminal Angioplasty Balloon vs Standard PTA for the Treatment of Obstructive Lesions in the Native Arteriovenous Dialysis Fistulae Drug Coated Balloon to treat obstruction of de novo or non-stented restenotic arteriovenous fistulae

Product Surveillance Registry (PSR) Platform Base Protocol

Double Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of Two Treatments of AMDC-USR with placebo in Female Subjects with Stress Urinary Incontinence.

Safety Assessment of MRI Imaging of All Body Parts in Patients with Implanted InterStim Therapy

Prospective cohort study embedded into integrated health care systems in the US to study cancer etiology, prevention, and early detection (Study Documentation avail-see Clinical Research)

Cystic Fibrosis Patient Registry

Observational Study of Telehealth for Remote Endpoint Assessment (OUTREACH)

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation

The Sanford Health BioBank

A Depression and Opioid Pragmatic Trial in Pharmacogenetics